Evidence map›Paper›PMID 42841389›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

The value of timely treatment with anti-amyloid therapy for Alzheimer's disease.

Jack M Chapel, Bryan Tysinger, Hossein Pourmand, Dana Goldman, Paul Aisen, Alzheimer's Disease Neuroimaging Initiative

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jack M ChapelSol Price School of Public Policy, University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0003-1543-9449
Bryan TysingerSol Price School of Public Policy, University of Southern California, Los Angeles, California, USA.
Hossein PourmandLeonard D. Schaeffer Institute for Public Policy and Government Service, University of Southern California, Los Angeles, California, USA.
Dana GoldmanSol Price School of Public Policy, University of Southern California, Los Angeles, California, USA.
Paul AisenLeonard D. Schaeffer Institute for Public Policy and Government Service, University of Southern California, Los Angeles, California, USA.
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
The United States Cost of Dementia Model: Quantifying Current and Future Impacts of Alzheimer’s Disease and Related DementiasU01AG086827 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DANA P GOLDMAN, JULIE M ZISSIMOPOULOS · 2024 to 2026
$4.7M
NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG086827NIA NIH HHS U01AG086827USC Schaeffer Center for Health Policy & Economics
6 · The paper itself

Abstract

introductionAnti-amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value.

methodsUsing dynamic microsimulation, we estimated the gross societal value of anti-amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression by 29% over individuals' remaining lifetime (baseline mean age: 73.0); earlier treatment initiated 2 years earlier.

resultsTreatment generated $104,885 (95% CI: $99,291, $110,479) in gross societal value over an individual's lifetime, including quality-of-life gains, reduced caregiving burden, and medical cost offsets driven by reduced nursing home use and Medicaid spending. Earlier treatment increased value 32%; this rose to 71% if treatment effects are also stronger (36% slowing) in earlier AD stages. Scenarios with 4-year effect duration yielded $49,122 (treatment) and $56,385 (earlier treatment). DISCUSSION: Timely treatment consistently increased long-term societal value. The findings provide a benchmark against which treatment implementation costs can be weighed.

Indexed as

Alzheimer DiseaseAgedCost-Benefit AnalysisDisease ProgressionFemaleHealth Care CostsHumansMaleQuality of LifeTreatment DelayUnited StatesAlzheimer's diseaseanti‐amyloid therapycare pathwaydonanemabmicrosimulationsocial value

Identifiers

PMID42841389
PMCPMC13643942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.